Poxel SA (FR:POXEL)
:POXEL
POXEL Stock Chart & Stats
€0.23
-€0.02(-8.98%)
At close: 4:00 PM EST
€0.23
-€0.02(-8.98%)
Day’s Range― - ―
52-Week Range€0.18 - €0.83
Previous CloseN/A
Volume292.16K
Average Volume (3M)288.32K
Market Cap
€17.14M
Enterprise Value€76.05M
Total Cash (Recent Filing)€2.06M
Total Debt (Recent Filing)€60.99M
Price to Earnings (P/E)―
Beta0.14
Next Earnings
Sep 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding53,758,167
10 Day Avg. Volume262,495
30 Day Avg. Volume288,318
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.11
Price to Sales (P/S)1.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercial Partnership With Sumitomo PharmaA revenue-generating, arm’s-length commercialization partnership in Japan provides durable non-dilutive cash via milestones/royalties and shifts commercialization burden to an established local partner. This reduces short-term capex needs and supports predictable collaboration receipts over coming quarters.
Sharp Revenue Rebound In 2024A material revenue inflection indicates commercial traction for marketed products or recognition of partnership receipts. Sustained top-line recovery over multiple quarters would improve operating leverage potential and validate the commercial model versus purely pre-revenue peers.
Focused Metabolic/NASH Clinical PipelineA coherent R&D focus on diabetes and NASH leverages prior regulatory/commercial experience with imeglimin and targets large, structural markets. Small‑molecule assets can be more cost-efficient to develop and attract partnering/licensing opportunities, supporting multiple long-term value pathways.
Bears Say
Highly Stressed Balance SheetDeep negative equity combined with rising debt materially limits financial flexibility, increasing refinancing and dilution risk. Over a multi‑month horizon this constrains runway for R&D and commercialization investments and raises the probability management must seek costly external funding.
Persistent Negative Operating Cash FlowSustained negative operating cash flow means the company cannot self-fund growth and depends on partners, milestone receipts, or financing. That reliance impairs long‑term planning, elevates dilution risk, and could limit ability to scale commercialization or fund pivotal trials without external capital.
Ongoing Unprofitability And Volatile MarginsDespite revenue gains, persistent negative profitability and historical margin swings indicate weak operating leverage and unstable unit economics. Over the medium term, sustainable value creation depends on consistent margin recovery and cost control, which are not yet demonstrated.
POXEL FAQ
What was Poxel SA’s price range in the past 12 months?
Poxel SA lowest stock price was €0.18 and its highest was €0.83 in the past 12 months.
What is Poxel SA’s market cap?
Poxel SA’s market cap is €17.14M.
When is Poxel SA’s upcoming earnings report date?
Poxel SA’s upcoming earnings report date is Sep 23, 2026 which is in 173 days.
How were Poxel SA’s earnings last quarter?
Currently, no data Available
Is Poxel SA overvalued?
According to Wall Street analysts Poxel SA’s price is currently Overvalued.
Does Poxel SA pay dividends?
Poxel SA does not currently pay dividends.
What is Poxel SA’s EPS estimate?
Poxel SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Poxel SA have?
Poxel SA has 53,758,167 shares outstanding.
What happened to Poxel SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Poxel SA?
Currently, no hedge funds are holding shares in FR:POXEL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Poxel SA
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is Imeglimin, an oral drug candidate, which completed Phase III clinical development stage in Japan, as well as in Phase III in the United States and Europe for the treatment of type 2 diabetes that improves pancreatic beta cell function, reduces insulin resistance, and decreases cardiovascular and metabolic disease risk factors, such as heightened blood lipid levels and excess body weight. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH). The company has a licensing agreement with Enyo Pharma S.A.S. for the development of PXL007 (EYP001), a synthetic non-steroidal and non-bile acid FXR agonist that is in Phase II study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.